Aridis Pharmaceuticals, INC

Aridis Pharmaceuticals has entered into a securities purchase agreement to sell 4,271,429 shares of common stock at $0.070 per share, raising approximately $0.30 million.

Aridis Pharmaceuticals held its annual meeting on January 12, 2024, where stockholders elected a director, ratified the appointment of an accounting firm, approved executive compensation, and approved the 2023 Omnibus Equity Incentive Plan.

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 11.43% in Aridis Pharmaceuticals, Inc. common stock as of March 31, 2026.

Armistice Capital and Steven Boyd report a continued 11.43% beneficial ownership stake in Aridis Pharmaceuticals, Inc. common stock.